CIRAX | MGBRX | CIRAX / MGBRX | |
Total Expense Ratio | 0.62 | 1.34 | 46% |
Annual Report Gross Expense Ratio | 0.62 | 1.44 | 43% |
Fund Existence | 24 years | 22 years | - |
Gain YTD | 15.337 | 11.781 | 130% |
Front Load | 4% | N/A | - |
Min. Initial Investment | 250 | 0 | - |
Min. Initial Investment IRA | N/A | N/A | - |
Net Assets | 118B | 1.25B | 9,425% |
Annual Yield % from dividends | 2.90 | 2.01 | 144% |
Returns for 1 year | 11.89 | 1.05 | 1,132% |
Returns for 3 years | 40.44 | 19.48 | 208% |
Returns for 5 years | 55.33 | 4.12 | 1,343% |
Returns for 10 years | 94.63 | 25.97 | 364% |
1 Day | |||
---|---|---|---|
ETFs / NAME | Price $ | Chg $ | Chg % |
GNOM | 37.99 | 0.91 | +2.44% |
Global X Genomics & Biotechnology ETF | |||
MQY | 11.19 | 0.15 | +1.36% |
Blackrock Muni Yield Quality Fund | |||
AVSD | 70.10 | 0.41 | +0.59% |
Avantis Responsible International Eq ETF | |||
VYM | 139.55 | 0.26 | +0.19% |
Vanguard High Dividend Yield ETF | |||
LGCF | 33.00 | N/A | N/A |
Themes US Cash Flow Champions ETF |